Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers

Vikas Ostwal, Akhil Kapoor, Reena Engineer, Avanish Saklani, Ashwin deSouza, Prachi Patil, Supreeta Arya, Suman Kumar Ankathi, Supriya Chopra, Mangesh Patil, Shanu Jain, Anant Ramaswamy

Abstract

Background: The optimal use and sequencing of short-course radiotherapy (SCRT) in metastatic rectal cancers (mRCs) are not well established.

Materials and Methods: We retrospectively reviewed the records of mRC patients receiving SCRT followed by palliative chemotherapy between January 1, 2013, and December 31, 2016, in Tata Memorial Hospital. Patients were classified as having “potentially resectable” disease (local and metastatic) or “unresectable” disease at baseline based on prespecified criteria. Results: A total of 105 consecutive patients were available for analysis. The median age of patients was 48 years (range: 16–62 years), and 57.1% were male patients. Signet ring histology was seen in 13.3% of patients. The most common site of metastases was liver limited (29.5%), non-loco-regional nodes (12.4%), and lung limited metastases (9.5%). Chemotherapeutic regimens administered were capecitabine-oxaliplatin (70.5%), modified 5 fluorouracil (5 FU)-leucovorin-irinotecan-oxaliplatin (10.5%), and modified 5 FU-leucovorin-irinotecan (8.6%). Targeted therapy accompanying chemotherapy was administered in 27.6% of patients. About 42.1% of patients with potentially resectable disease and 11.1% with the unresectable disease at baseline underwent curative-intent resection of the primary and address of metastatic sites. With a median follow-up of 18.2 months, median overall survival (OS) was 15.7 months (95% confidence interval: 10.42–20.99). Patients classified as potentially resectable had a median OS of 32.62 months while patients initially classified as unresectable had a median OS of 13.04 months (P = 0.016). The presence of signet ring morphology predicted for inferior mOS (P = 0.021). Conclusions: SCRT followed by systemic therapy in mRC is a feasible, efficacious paradigm for maximizing palliation, and achieving objective responses. The classification of patients based on resectability was predictive of actual resection rates as well as outcomes. Signet ring mRC show inferior outcomes in this cohort of patients.

Key words: Chemotherapy, metastatectomy, metastatic rectal cancers, resectability, short-course radiotherapy

Introduction

Outcomes in metastatic colorectal cancers (mCRCs) have improved with the greater use of chemotherapy, monoclonal antibodies and recently, immunotherapy.[1-4] Increasing resection rates for resectable liver metastases (LM) (up to 93%) and conversion rates for unresectable LM (up to 49%) to resectability by chemotherapy with or without monoclonal antibodies means that there is a need for addressing the rectal primary adequately as well.[5-8] There also remains the unanswered question of potential benefit with surgical resection of the primary in patients with the unresectable metastatic disease with multiple retrospective studies suggesting a survival benefit for the strategy.[9,10] There are also no firm guidelines regarding criteria for resectability of metastatic sites in CRC, though few exist for liver metastatectomy.

The effect of radiotherapy (RT) in the local symptom and disease control of locally advanced rectal cancers (LARCs) has ensured that it is a part of the standard of care in the treatment of such cancers. While conventionally preoperative long-course chemoradiation (LCRT) was part of the treatment paradigm for LARC, there is growing evidence to suggest comparability and potential superiority of preoperative short-course RT (SCRT) and systemic chemotherapy as opposed to LCRT.[11-13] In patients with metastatic rectal cancer (mRC) at baseline, upfront SCRT provides palliation, potential stoma prevention besides avoiding undue delays in beginning systemic chemotherapy (with or without targeted therapy). It also overcomes the logistic constraints of combining RT for the primary rectal cancer and preparing the patient for potential surgery of the primary should there be adequate conversion/downtaging of primary and secondary sites post chemotherapy.[14,15]

Materials and Methods

Patient selection

The study is a retrospective analysis of mRC patients with metastases who were offered SCRT followed by chemotherapy, (with or without monoclonal antibodies based on feasibility) during January 1, 2013, to December 31, 2016, at the Department of Gastrointestinal Oncology, Tata Memorial Hospital (TMH) in Mumbai. The study was approved by the Institutional Review Board and Ethics Committee (IEC/0516/1664/001) and was conducted as per the Declaration of Helsinki guidelines. Patient data were extracted from a prospectively maintained rectal cancer database at TMH. Patients included in the study satisfied all the following criteria:

1. Histologically confirmed adenocarcinoma of the rectum, either T3/T4 and or node (N) positive as per clinical diagnosis and contrast-enhanced magnetic resonance imaging (CE-MRI) of the rectum
2. Evidence of metastases based on contrast-enhanced computed tomography (CT) scans or 18-fluorodeoxyglucose contrast-enhanced positron emission tomography scan.

Institution criteria for the potential liver-directed therapy of metastatic liver disease

1. Technically R0 resection possible of all visible lesions
2. Greater than 30% future liver remnant (FLR) post planned resection at baseline or >40% FLR postchemotherapy

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Ostwal V, Kapoor A, Engineer R, Saklani A, deSouza A, Patil P, et al. Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers. South Asian J Cancer 2019;8:92-7.
3. Size of hepatic lesions <5 cm and/or <4 LM
4. Lesions in proximity to all hepatic veins or both branches of the portal vein, which may undergo potential downstaging and further resection.

Patients not satisfying the above criteria were classified as unresectable metastatic disease, though a surgical evaluation was considered at a later point for all patients if they had a good response at metastatic sites and controlled primary.

**Resectability criteria of the primary rectal cancer**
1. Circumferential margin (CRM) negativity
2. The absence of extension through the greater sciatic notch, encasement of external iliac vessels, paraaortic lymphadenopathy, or sacral invasion above S2–S3 junction
3. R0 resection possible.

Patients with extensive side-wall involvement were considered for local resection based on a case-to-case scenario.

**Short-course radiotherapy protocol**
Patients received SCRT to a dose of 5 Gy per fraction for a total of five fractions given on 5 consecutive days.

**Systemic chemotherapy protocol**
Patients were planned for starting chemotherapy 5–10 days postcompletion of SCRT. Targeted therapy was added to chemotherapy backbone based on results of mutation testing. Regimens considered as first-line therapy in our institution include capcitabine-oxaliplatin (CAPOX), single-agent capcitabine, 5 fluorouracil (5 FU)-leucovorin-oxaliplatin (FOLFOX-7), modified 5 FU-leucovorin-irinotecan (mFOLFIRI without bolus 5 FU), and modified 5 FU-leucovorin-irinotecan-oxaliplatin (mFOLIRINOX without bolus 5 FU). Dosages and schedules were as per standard schedules. Toxicity assessment during chemotherapy was done at every patient visit and recorded as per NCI-CTCAE (National Cancer Institute- Common Terminology Criteria for Adverse Events).

**Tumor response assessment**
CT scans were reported as per RECIST 1.1 criteria.[16] In situations where response could not be quantified by RECIST, then the response was quantified based on collusion between treating physician and the gastrointestinal radiologist as follows: complete response (CR) – disappearance of all baseline lesions; partial response (PR) – significant regression of lesions at baseline; stable disease (SD) – no significant regression of baseline lesions and no new lesions; progressive disease (PD) – appearance of new lesions or significant increase in baseline lesions. Responses in the rectal primary were evaluated by CE-MRI and responses were recorded as CR, PR, SD, or PD based on changes in signal tumor intensity, regression in tumor and nodal size, regression in CRM status and the presence of fibrosis on T2-weighted sequences.[17,18]

**Prognostic factors**
Predefined prognostic factors evaluated for correlation with overall survival (OS) were younger age at diagnosis (≤50 years vs. >50 years), degree of differentiation, signet ring histology, Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0/1 vs. ≥2), and the presence of obstruction at baseline and resectability status potentially resectable versus unresectable metastatic disease at baseline.

**Clinical data collection and statistics**
All data were entered in IBM Statistical Package for the Social Sciences (SPSS) software version 21.0 and used for analysis. Descriptive statistics including median, frequency, and percentage for categorical variables is used to describe age, gender distribution, treatment, and response to treatment. Survival outcomes in terms of event-free survival (EFS) and OS were analyzed. Median EFS was calculated from the date of diagnosis to the date of clinical or radiological evidence of disease progression or the last follow-up date. Median OS was calculated from the date of diagnosis until the last follow-up or death. EFS and OS were calculated separately for the potentially resectable and unresectable cohorts. Survival analysis was performed using Kaplan–Meier estimates and log-rank test for bivariate comparisons. Variables achieving statistical significance ($P \leq 0.05$) on univariate analysis were evaluated for multivariate analysis by the cox-regression.

**Results**

**Baseline characteristics**
A total of 105 patients were included in the study in the specified time. Baseline demographic and clinical characteristics are detailed in Table 1.

**Delivery of short-course radiotherapy and first line systemic therapy**
SCRT was delivered as planned in all 105 patients, with no Grade 3 or Grade 4 toxicities. There were no unplanned delays in SCRT. The mean duration between completion of SCRT and beginning systemic therapy was 8 days (range: 2–22). The chemotherapy regimens used were as follows:
- CAPOX (70.5%)
- Modified FOLFOX (10.5%)
- Modified FOLFIRI (8.6%)
- Modified FOLFOX (5.7%)
- Capecitabine monotherapy (4.8%).

Common Grade 3 and Grade 4 toxicities as well as the requirement of dose reductions are provided in Table 2.

**Response rates, resection rates, and treatment of metastatic sites**
Post-SCRT and chemotherapy, responses rates and disease control rates at primary and metastatic sites are shown in Table 2.

In patients with potentially resectable disease ($n = 38$), 16 patients (42.1%) underwent curative-intent resection of the primary. In patients with baseline unresectable disease ($n = 67$), 8 patients (11.1%) underwent curative-intent resection of the primary. In these patients, details of surgery of the primary site as well as treatment of metastatic sites are described in Supplementary Table 1.

**Overall survival and event-free survival**
With a median follow-up 18.2 months, 59 patients had died of disease for a median OS of 15.7 months (95% confidence interval [CI]: 10.42–20.99). Patients classified as potentially resectable at baseline had a median OS of 32.62 months (95% CI: 17.7–47.5) whereas patients initially classified as...
unresectable had a median OS of 13.04 months (95% CI: 10.2–15.8) with a statistically significant difference in survival between the cohorts \((P = 0.016)\). Patients who underwent resection of the primary rectal cancer from the entire cohort \((n = 24)\) had a statistically superior survival compared to patients who did not undergo surgery of the primary \((n = 81)\) (2-year survival 58% vs. 10.7%; \(P < 0.001)\).

At the time of median follow-up, 67 patients had an event for median EFS of 10.84 months (95% CI: 9.10–12.58). Patients classified initially as potentially resectable had a median EFS of 13.44 months \((95\% \text{ CI}: \text{7.5–19.4})\) while patients classified as unresectable had a median EFS of 9.76 months \((95\% \text{ CI}: \text{8.4–11.1})\), and this difference was statistically significant \((P = 0.030)\). Patients who underwent resection had a median EFS of 22.9 months as compared to a median EFS of 7.8 months in patients who did not undergo resection of the primary \((P < 0.001)\).

**Prognostic factors for overall survival**

Of the prognostic factors elevated, on univariate analysis, younger age (<50 years) \((P = 0.021)\), and presence of signet ring histology \((P = 0.010)\), predicted for a statistically significant inferior OS, while potential resectability status at baseline predicted for a superior OS \((P = 0.016)\). On multivariate analysis, the presence of signet ring morphology \((P = 0.021)\) and resectability status at baseline \((0.027)\) retained their statistical significance for OS [Table 3].

**Discussion**

The sequence of SCRT followed by palliative chemotherapy in mRC is suggested by the ESMO treatment guidelines.

---

**Table 1: Baseline demographic and clinical characteristics**

| Characteristic                        | \(n\) (percentage where applicable) |
|---------------------------------------|-------------------------------------|
| Median age (years)                    | 48 (range: 16–78)                   |
| <50                                   | 60 (57.1)                           |
| \(\geq 50\)                           | 45 (42.9)                           |
| Gender                                |                                     |
| Male                                  | 60 (57.1)                           |
| Female                                | 45 (42.9)                           |
| ECOG PS                               |                                     |
| 0/1                                   | 37 (35.3)                           |
| \(\geq 2\)                            | 68 (64.7)                           |
| 2                                     | 60 (57.1)                           |
| 3                                     | 8 (7.6)                             |
| Site of disease                       |                                     |
| Upper 1/3                             | 42 (40)                             |
| Middle 1/3                            | 17 (16)                             |
| Lower 1/3                             | 46 (44)                             |
| Histopathology                        |                                     |
| PDAC                                  | 36 (34.3)                           |
| MDAC                                  | 43 (41)                             |
| WDAC                                  | 24 (22.9)                           |
| Adenocarcinoma, NOS                   | 2 (1.9)                             |
| Mucinous histology                    |                                     |
| Yes                                   | 8 (7.6)                             |
| No                                    | 97 (92.4)                           |
| Signet ring histology                 |                                     |
| Yes                                   | 14 (13.3)                           |
| No                                    | 91 (86.7)                           |
| Baseline CEA status                   |                                     |
| CEA=ULN                               | 88 (83.8)                           |
| CEA<ULN                               | 17 (16.2)                           |
| Baseline obstruction requiring diversion stoma |           |
| Yes                                   | 61 (58.1)                           |
| No                                    | 44 (41.9)                           |
| Metastatic sites of disease           |                                     |
| Liver limited                         | 31 (29.5)                           |
| Lung limited                          | 10 (9.5)                            |
| Non loco-regional nodes               | 13 (12.4)                           |
| Peritoneal limited                    | 6 (5.7)                             |
| Others                                | 3 (2.9)                             |
| >1 site of disease                    | 42 (40)                             |
| Metastatic resectability status at baseline |             |
| Potentially resectable                | 38 (36.2)                           |
| Unresectable                          | 67 (63.8)                           |

ECOG PS = Eastern Oncology Group performance status, PDAC = Poorly differentiated adenocarcinoma, MDAC = Moderately differentiated adenocarcinoma, WDAC = Well differentiated adenocarcinoma, NOS = Not otherwise specified, ULN = Upper limit of normal, CEA = Carcinoembryonic antigen

---

**Table 2: Characteristics of first line systemic therapy postshort course radiotherapy and response rates**

| Characteristics                        | \(n\) (percentage where applicable) |
|----------------------------------------|-------------------------------------|
| Chemotherapeutic regimen               |                                     |
| CAPOX                                  | 74 (70.5)                           |
| FOLFIRINOX                             | 11 (10.5)                           |
| FOLFIRI                                | 9 (8.6)                             |
| FOLFOX                                 | 6 (5.7)                             |
| Capecitabine                           | 5 (4.8)                             |
| Targeted therapy (with chemotherapy backbone) |                         |
| Bevacizumab                            | 29 (27.6)                           |
| Cetuximab                              | 24 (5.5)                            |
| Grade 3 and 4 toxicities               |                                     |
| Hematological                          | 4 (4)                               |
| Vomiting                               | 4 (4)                               |
| Diarrhoea                              | 17 (16.2)                           |
| Hand foot syndrome                     | 11 (10.5)                           |
| (Grade 2 and Grade 3)                  |                                     |
| Fatigue (Grade 3)                      | 2 (1.3)                             |
| Response rates in primary              |                                     |
| CR                                     | 3 (2.9)                             |
| PR                                     | 38 (36.2)                           |
| SD                                     | 31 (29.5)                           |
| PD                                     | 27 (25.7)                           |
| RR                                     | 41 (39.1)                           |
| DCR                                    | 72 (68.6)                           |
| Not evaluated                          | 4 (3.8)                             |
| Lost to follow-up                      | 2 (1.9)                             |
| Response rates in metastatic sites     |                                     |
| Complete response                      | 2 (1.9)                             |
| Partial response                       | 27 (25.7)                           |
| Stable disease                         | 25 (23.8)                           |
| Progressive disease                    | 43 (41.0)                           |
| Response rates                         | 29 (27.6)                           |
| DCR                                    | 54 (51.4)                           |
| Not available                          | 6 (5.6)                             |
| Lost to follow-up                      | 2 (2.0)                             |

CAPOX = Capecitabine-oxaliplatin, FOLFIRINOX = Fluorouracil-leucovorin-irinotecan-oxaliplatin, FOLFIRI = Fluorouracil-leucovorin-irinotecan, FOLFOX = Fluorouracil plus oxaliplatin, CR = Complete response, PR = Partial response, SD = Stable disease, PD = Progressive disease, RR = Response rates, DCR = Disease control rate
and offers the paradigm of addressing the primary upfront regarding local control, and palliation, without delaying systemic chemotherapy. If initial systemic treatment entails chemotherapy alone, downstaging to resectability is about 22% as opposed to about 49% with chemotherapy-targeted therapy combinations.

The salient features of the studies we selected for evaluation and comparison with the current study. The striking clinical features at baseline in patients in the current study are the younger age at diagnosis (median age ~48 years), a high number of patients with ECOG PS ≥2 (64.7%), the high incidence of signet ring cancers (13.3%) and presence of obstruction requiring the creation of a stoma (58.1%). Such clinical factors suggest a different disease presentation, increased burden of disease and potentially, biology especially signet ring histology, as compared to published data from Western trials as well as the studies shown for comparison. SCRT in our cohort was tolerated well, with no delays in the initiation of systemic therapy. This is line with the philosophy of addressing the primary tumor early with no undue delay in the initiation of systemic therapy. A majority of patients were treated with CAPOX chemotherapy as the first line, which is in keeping with recommendations for the first line therapy for mCRC. A small number of patients were treated with CAPOX plus bevacizumab as the first line.

Table 3: Univariate and multivariate analysis of prognostic factors for overall survival

| Characteristic                              | OS (months) | P (univariate analysis) | P (multivariate analysis) | Hazard ratio (95% CI) |
|---------------------------------------------|-------------|-------------------------|---------------------------|-----------------------|
| Age (years)                                 |             |                         |                           |                       |
| <50                                         | 12.06       | 0.021                   | 0.134                     | 0.66 (0.377-1.139)    |
| ≥50                                         | 21.42       |                         |                           |                       |
| Degree of differentiation (n=3)             |             |                         |                           |                       |
| PDAC                                        | 12.65       | 0.481                   |                           |                       |
| MDAC/WDAC                                   | 16.66       |                         |                           |                       |
| Signet ring histology                       |             |                         |                           |                       |
| Present                                    | 10.22       | 0.010                   | 0.021                     | 1.46 (1.060-2.015)    |
| Absent                                     | 18.73       |                         |                           |                       |
| Baseline elevated CEA                       |             |                         |                           |                       |
| Yes                                        | 13.7        | 0.343                   |                           |                       |
| No                                         | 23.10       |                         |                           |                       |
| ECOG PS                                     |             |                         |                           |                       |
| 0,1                                        | 14.16       | 0.888                   |                           |                       |
| ≥2                                         | 16.40       |                         |                           |                       |
| Baseline obstruction                        |             |                         |                           |                       |
| Present                                    | 15.70       | 0.392                   |                           |                       |
| Absent                                     | 22.77       |                         |                           |                       |
| Resectability status at baseline            |             |                         |                           |                       |
| Potentially resectable                      | 32.62       | 0.016                   | 0.027                     | 1.95 (1.080-3.511)    |
| Unresectable                                | 13.04       |                         |                           |                       |

ECOG PS=Eastern oncology group performance status, PDAC=Poorly differentiated adenocarcinoma, MDAC=Moderately differentiated adenocarcinoma, WDAC=Well differentiated adenocarcinoma, CI=Confidence interval, OS=Overall survival, CEA=Carcinoembryonic antigen

Table 4: Studies evaluating short-course radiotherapy and systemic chemotherapy in metastatic rectal cancers

| Characteristic                              | Van Dijk et al. | Tyc-Szczepaniak et al. | Yoon et al. | Current TMH study |
|---------------------------------------------|-----------------|------------------------|-------------|-------------------|
| Study type                                  | Phase II, single arm | Phase II, single arm | Retrospective | Retrospective     |
| Number of patients                          | 40              | 50                     | 50          | 105               |
| ECOG PS (%)                                 |                 |                        |             |                   |
| 0/1                                         | 27 (71)         | 50 (100)               | 50 (100)    | 37 (35.3)         |
| ≥2                                          | 11 (29)         | 0                      | 0           | 68 (64.7)         |
| Sequence of treatment                       | RT >chemotherapy| RT >chemotherapy plus bevacizumab | Chemotherapy +/- targeted therapy>RT | RT >chemotherapy +/- targeted therapy |
| Systemic therapy regimen                    | Predominantly CAPOX plus bevacizumab | Predominantly FOLFOX with or without cetuximab/bevacizumab | Predominantly CAPOX with or without cetuximab/bevacizumab |
| Use of targeted therapy (%)                 | 0               | 50 (100)               | 11 (22)     | 29 (27.6)         |
| Radiotherapy regimen                        | 5×5 Gy          | 5×5 Gy                 | 5×5 Gy      | 5×5 Gy            |
| Resectability status of metastases at baseline | 100% unresectable | 100% resectable or potentially resectable | 70% curable | 36.2% potentially resectable |
| Creation of stoma post-SCRT (%)             | 8 (20)          |                        | -           | 0 (n=71)          |
| Curative resection of primary (%)           | 0               | 36 (72)                | 41 (82)     | 24 (22.9)         |
| 2 (year) OS (%)                             | 30              | 80                     | 73.9        | 33.2              |

ECOG PS=Eastern oncology group performance status, RT=Radiotherapy, CAPOX=Capecitabine plus oxaliplatin, FOLFOX = 5-Fluorouracil plus oxaliplatin, OS=Overall survival, TMH=Tata memorial hospital, SCRT=Short-course radiotherapy
of patients were also treated with the mFOLFOXIRINOX regimen, considering the regimen’s potentially greater cytoreductive capability.\textsuperscript{[7,29,36]} While the hematological toxicities in our study were manageable, one-quarter of patients required dose-reductions, either upfront or during chemotherapy. Primary reasons were an attempt at the safe administration in patients with borderline (ECOG PS $\geq$2–64.7%) as well as nonhematological toxicities such as diarrhea (grade 3/4 – 16.2%) and HFS (Grade 2/3 – 10.5%). Besides baseline ECOG PS being a predictor for tolerance issues with chemotherapy, we have previously shown that homozygous DPD mutations may have a slightly higher prevalence in Indian patients – these reasons may account for the incidence of nonhematological toxicities seen.\textsuperscript{[31-34]} Targeted therapy was used in only 27% of patients, predominantly being bevacizumab. Use of targeted therapy is limited, especially in low-middle-income countries.\textsuperscript{[35-37]} As compared to the current study, the study by van Dijk \textit{et al.} used targeted therapy in 100% of their patients, while the South Korean study used targeted therapy in a comparable 22% of patients.\textsuperscript{[38]}

The prespecified criteria for resectability clearly predicted for significantly increased use of liver-directed therapy (LDT) (42.1% in potentially resectable group vs. 11.1% in unresectable group) and more importantly, statistically different survival outcomes (32.62 months vs. 13.04 months; $P = 0.016$). While there are no uniform criteria for selecting patients for LDT, our institution criteria is practical and easy to use a combination of pre- and post-therapy points of reference for selection of patients.\textsuperscript{[6,7,23,24,38]} We acknowledge that our institution criteria need further validation prospectively, whereas at the same time pointing out that criteria for liver resection have differed across studies and institutions.

A total of 24 patients (22.9%; $n = 105$) of patients in the entire cohort of the study underwent resection of the primary and treatment of the metastases as well. While prospective studies have shown conversion rates (to metastasectomy) of 33%–61% in patients with liver-limited disease,\textsuperscript{[7,29,40]} a significant proportion of patients in this cohort had greater than one site of disease (40%), lung lesions (35.2%), and <5 liver lesions (55.9%; $n = 59$). Such a cohort is representative of an mRC cohort as against a truly oligometastatic disease cohort. The disease burden of patients in the current study (63.8% unresectable) cohort is closer to the patients in the study by Tyc-Szczezpaniak \textit{et al.} (100% unresectable) than the other studies shown for comparison. With the confines of such a flawed cross-study comparison, the resection rates of 22.9% are indicative of the feasibility of such sequencing of therapy. The studies by van Dijk \textit{et al.} (100%) and Yoon \textit{et al.} (70%) clearly had more patients with resectable metastatic disease, and this bears out in the final resectability rates [Table 4].

The median EFS (10.84 months) and OS (15.7 months) of the entire cohort is a reflection of patients being treated predominantly with chemotherapy and having the majorly unresectable metastatic disease.\textsuperscript{[41-43]} Going beyond OS, the combination of upfront SCRT and systemic therapy allowed for good local control rates (primary disease control rates – 68.6%), effective palliation of the primary as well avoidance of palliative surgery postbeginning of treatment. Higher incidence of signet ring cancers and their inferior outcomes (10.22 months vs. 18.73 months) suggests the need for a different approach to treating these cancers as shown in previous studies as well.\textsuperscript{[44,45]}

The current study has multiple limitations, and caveats exist considering the retrospective nature of the study. The patients in this study are clearly a heterogeneous cohort with multiple sites of disease; metastasectomy of sites beyond the liver is not a uniform option in patients with mCRC. While the criteria for LDT used was uniform, this needs refinement and validation in a larger cohort of patients as only 42.1% of patients with potentially addressable secondary sites finally underwent resection of primary and secondaries. We are also unable to speculate as to the actual number of patients in whom a stoma was avoided, i.e., identification of a cohort of near obstructed patients.

\section*{Conclusions}

The study suggests that’s SCRT followed by systemic therapy in mRCs is a feasible, efficacious paradigm for maximizing palliation and objective responses. The classification of patients based on resectability was predictive of actual resection rates as well as outcomes. Signet ring mRC show inferior outcomes in this cohort of mRC patients.

\section*{Financial support and sponsorship}

Nil.

\section*{Conflicts of interest}

There are no conflicts of interest.

\section*{References}

1. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, \textit{et al}. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:2240-7.

2. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, \textit{et al}. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75.

3. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, \textit{et al}. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: A randomized clinical trial. JAMA 2017;317:2392-401.

4. Diaz LA, Marabelle A, Delord JP, Shapira-Frommer R, Geva R, Peled N, \textit{et al}. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol 2017;35 15 Suppl: 3071.

5. Gruenerberg B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, cetapacitase, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:1830-5.

6. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): A randomised controlled trial. Lancet 2008;371:1007-16.

7. Gruenerberg T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFEX-6 or FOLFIRI6 in patients with initially unresectable liver metastases from colorectal cancer: The OLIVIA multinational randomised phase II trial. Ann Oncol 2015;26:702-8.

8. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386-422.

9. Verhoeof C, de Witt JH, Burger JW, Verheul HM, Koopman M. Surgery of South Asian Journal of Cancer ♦ Volume 8 ♦ Issue 2 ♦ April-June 2019
Upfront Long-term results of a randomized trial

Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: Retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 2011;18:3252-60.

Folkesson J, Birgisson J, Pahlman L, Cederman B, Gilmeilius B, Gunnarsson U, et al. Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;23:5644-50.

Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:12-15.

Bujko K, Wyrwicz L, Rutkowski A, Malinowska A, Pietrzak L, Kryński J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemoradiotherapy for ct4 or fixed ct3 rectal cancer: Results of a randomized phase II study. Ann Oncol 2013;24:8229-34.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.

Patel UB, Blomqvist LK, Taylor F, George C, Guthrie A, Bees N, et al. MRI after treatment of locally advanced rectal cancer: How to report tumor response – The MERCURY experience. AJR Am J Roentgenol 2012;199:W486-95.

Arya S, Das D, Engineer R, Saklani A. Imaging in rectal cancer with emphasis on local staging with MRI. Indian J Radiol Imaging 2015;25:148-61.

Glyme-Jones R, Wyrwicz L, Tirtel E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:v32-40.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Colorectal carcinoma in young adults: A retrospective study on clinicopathological and corresponding genetic features of colorectal cancer of the rectum. BMC Cancer 2015;15:764.

Bachtel JB, Lucidarme O, Taleib J, Maillard E, Levache BC, Raoul JL, et al. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial. J Clin Oncol 2016;34 15 Suppl: 3513.

Sahu A, Ramaswamy A, Ostwal V. Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: A tertiary centre experience. J Gastrointest Oncol 2016;7:380-6.

Crosara Teixeira M, Marques DF, Ferrari AC, Alves MF, Alex AK, Sabbaga J, et al. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4. Clin Colorectal Cancer 2015;14:52-7.

Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 2015;1:778-84.

Watanabe A, Yang C, Cheung WY. ECOCO performance status as a predictor of adjuvant chemotherapy (AC) toxicities in stage III colorectal cancer (CRC) patients. J Clin Oncol 2017;35 4 Suppl: 789.

Ghosh J, Gupta S, Desai S, Shet T, Radvakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. J Oncol 2011;48:391-6.

Parikh RC, Du XL, Morgan RO, Lairon DR. Patterns of treatment sequences in chemotherapy and targeted biologics for metastatic colorectal cancer: Findings from a large community-based cohort of elderly patients. Drugs Real World Outcomes 2016;3:69-82.

Ignacio DN, Griffin JJ, Daniel MG, Serlemitsos-Day MT, Lombardo FA, Alleyne TA, et al. Evaluation of treatment strategies for head and neck cancer in an African American population. West Indian Med J 2013;62:504-9.

Maor Y, Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol 2013;2013:81505.

Garufi C, Torsello A, Tumolo S, Etterre GM, Zeuli M, Campanella C, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010;103:1542-7.

Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFIRI/CEP13585/CEP1706 in a multicentric, open-label, randomized, phase 3 trial. J Clin Oncol 2015;33:1927-35.

Colucci G, Gobia V, Paoletti G, Giuliani F, Caruso M, Gobbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-75.

Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Llorca G, Busuiquer I, et al. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 2005;5:263-7.

Ostwal V, Engineer R, Ramaswamy A, Sahu A, Zanwar S, Arya S, et al. Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX? J Gastrointest Oncol 2016;7:958-67.

Gupta S, Bhattacharya D, Acharya AY, Majumdar S, Ranjan P, Das S, et al. Colorectal carcinoma in young adults: A retrospective study on Indian patients: 2000-2008. Colorectal Dis 2010;12:e182-9.

Tajiri K, Sudou T, Fujita F, Hisaka T, Kinugasa T, Akagi Y, et al. Clinicopathological and corresponding genetic features of colorectal signet ring cell carcinoma. Anticancer Res 2017;37:3817-23.